Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Zoetis ( (ZTS) ) is now available.
Zoetis Inc. announced the appointment of Stephanie Tilenius to its Board of Directors, effective December 1, 2025, increasing the board size from 12 to 13 members. Tilenius, a seasoned entrepreneur with extensive experience in digital health and AI, is expected to contribute significantly to Zoetis’ digital transformation and innovation strategy in the animal health industry, aligning with the company’s vision to leverage technology for improved animal care.
The most recent analyst rating on (ZTS) stock is a Buy with a $166.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.
Spark’s Take on ZTS Stock
According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.
Zoetis demonstrates strong financial performance and a positive outlook from its recent earnings call, which are the most significant factors driving the score. The technical analysis suggests a neutral trend, while the valuation indicates a premium pricing. Despite some challenges, the company’s strategic focus and raised guidance support a favorable stock assessment.
To see Spark’s full report on ZTS stock, click here.
More about Zoetis
Zoetis is the world’s leading animal health company, dedicated to advancing care for animals through innovative solutions. With a history of over 70 years, Zoetis offers a comprehensive portfolio of medicines, vaccines, diagnostics, and technologies, impacting over 100 countries. In 2024, the Fortune 500 company generated $9.3 billion in revenue and employed approximately 13,800 people.
Average Trading Volume: 2,952,289
Technical Sentiment Signal: Sell
Current Market Cap: $64.68B
For a thorough assessment of ZTS stock, go to TipRanks’ Stock Analysis page.